Time To Response In Patients With Advanced Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small-Cell Lung Cancer (NSCLC) Receiving Alectinib In The Phase II NP28673 And NP28761 Studies

INTRODUCTION: Alectinib is a highly selective and potent ALK inhibitor, approved for the treatment of patients with metastatic ALK+ NSCLC based on results from the Phase II global NP28673 (NCT01801111) and North American NP28761 (NCT01871805) studies. METHODS: This exploratory analysis of two Phase...

Descripción completa

Detalles Bibliográficos
Autores principales: Gadgeel, Shirish, Shaw, Alice T, Barlesi, Fabrice, Crino, Lucio, Yang, James CH, Dingemans, Anne-Marie, Kim, Dong-Wan, de Marinis, Filippo, Schulz, Mathias, Liu, Shiyao, Gupta, Ravindra, Smoljanovic, Vlatka, Ou, Sai-Hong Ignatius
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6859466/
https://www.ncbi.nlm.nih.gov/pubmed/32009824
http://dx.doi.org/10.2147/LCTT.S209231

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6859466/
https://www.ncbi.nlm.nih.gov/pubmed/32009824
http://dx.doi.org/10.2147/LCTT.S209231

Ejemplares similares